ISCO · XBRL financial data

International Stem Cell financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ISCO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	7,128	7,176	8,180	7,789	9,085	9,100
Cost of revenue	2,781	2,935	3,269	3,181	3,764	4,033
Research and development	988	695	492	511	657	684
General and administrative	4,422	4,084	3,357	3,514	3,516	3,532
Operating income (loss)	(2,818)	(1,921)	(183)	(663)	(68)	(267)
Interest expense	113	128	135	139	145	151
Other income (expense)	—	13	(13)	8	4	—
Income tax expense (benefit)	—	—	—	—	0	0
Net income (loss)	(2,724)	(899)	(331)	(131)	(209)	(418)
Earnings per share, basic USD per share	—	(0.11)	(0.04)	(0.02)	(0.03)	(0.05)
Earnings per share, diluted USD per share	—	(0.11)	(0.04)	(0.02)	(0.03)	(0.05)
Weighted average shares, basic thousands of shares	—	7,833	8,004	8,004	8,004	8,004
Weighted average shares, diluted thousands of shares	—	7,833	8,004	8,004	8,004	8,004

Fiscal years (ISCO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	689	171	742	1,588	1,230	993
Accounts receivable	403	844	747	574	1,058	723
Inventory	917	1,184	1,384	1,263	1,149	1,514
Prepaid and other current assets	174	135	90	96	123	181
Total current assets	2,183	2,334	2,963	3,521	3,560	3,411
Property and equipment, net	534	384	248	215	257	160
Right-of-use asset	874	868	727	557	352	344
Total assets	5,287	4,946	5,135	5,390	5,173	4,819
Accounts payable	360	508	322	364	186	168
Accrued liabilities	386	404	508	485	527	428
Total current liabilities	1,483	4,284	4,635	4,832	4,688	4,579
Lease liability, non-current	845	950	720	445	115	0
Total liabilities	5,320	5,234	5,355	5,277	4,803	4,579
Accumulated deficit	(109,115)	(110,014)	(110,345)	(110,476)	(110,685)	(111,103)
Total stockholders' equity	(4,333)	(4,588)	(4,520)	(4,187)	(3,930)	(4,060)
Total liabilities and equity	5,287	4,946	5,135	5,390	5,173	4,819
Common shares outstanding (cover page) thousands of shares	7,539	8,004	8,004	8,004	8,004	8,004

Fiscal years (ISCO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(2,724)	(899)	(331)	(131)	(209)	(418)
Stock-based compensation	1,279	644	399	464	466	288
Depreciation and amortization	253	262	218	194	206	219
Net cash from operating activities	(341)	(1,297)	332	929	13	8
Purchases of property and equipment	28	23	1	80	166	43
Net cash from investing activities	(108)	(45)	(11)	(83)	(171)	(45)
Proceeds from long-term debt	654	—	—	—	—	—
Net cash from financing activities	654	824	250	—	(200)	(200)
Net change in cash	205	(518)	571	846	(358)	(237)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
International Stem Cell	1,089	2,675	167*	8.0M	—	Q2 FY26 10-QJun 30, 2026
Emmaus Life Sciences	2,808	6,318	1,693*	70.2M	—	Q2 FY26 10-QJun 30, 2026
Avenue Therapeutics	1,942	0	(475)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
Nutra Pharma	not reported	34	(251)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Mosaic ImmunoEngineering	0	not reported	(0)*	7.2M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
China Foods Holdings	16	0	(94)*	20.3M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Hepion Pharmaceuticals	1,629	not reported	(1,394)*	90.2M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Evoke Pharma	11,576	4,284	(522)*	1.7M	22.2 quarters	Q3 FY25 10-QSep 30, 2025
Twinlab Consolidated Holdings	13	not reported	(907)*	259.1M	0.0 quarters	Q4 FY24 10-KDec 31, 2024

Not investment advice. Not affiliated with the U.S. SEC.